STOCKS TELEGRAPH

Tag: VERO stock price

  • Venus Concept (VERO) Stock Gains Momentum After Strategic Asset Sale

    Venus Concept (VERO) Stock Gains Momentum After Strategic Asset Sale

    The news of a strategic asset sale caused Venus Concept Inc. (NASDAQ: VERO) to see a sharp increase in the value of its shares. At $3.57, shares of VERO had experienced a remarkable 49.37% rise as of the most recent market check.

    Strategic Diversification Increases Market Trust

    Following a definitive agreement to sell its Venus Hair division to MHG Co. Ltd., commonly known as Meta Healthcare Group, for $20 million in total cash, subject to standard working capital adjustments, the momentum has been building.

    It is anticipated that the transaction’s net proceeds would strengthen Venus Concept’s balance sheet and supply vital capital for upcoming key expansion projects. The company’s larger analysis of strategic options with the goal of optimizing shareholder value includes this divestment.

    Venus Concept intends to simplify operations and focus on its primary medical aesthetics business by selling off the Venus Hair division. The action is expected to boost long-term profitability, lower operating costs, and increase revenue.

    Increasing Share in Hair Restoration Market

    Through the acquisition, Meta Healthcare Group will secure ownership of Meta Robotics LLC, a newly formed subsidiary of Venus Concept. This includes the complete portfolio of hair restoration and transplant technologies—ARTAS and NeoGraft—as well as associated intellectual property, equipment, and service infrastructure.

    These technologies are recognized for their strong market presence across Asia, Europe, and North America, supported by loyal customer bases and brand recognition.

    Future Collaboration and Operational Continuity

    As part of the agreement, Meta Healthcare Group will grant Venus Concept a perpetual, royalty-free, worldwide license to a subset of the transferred patents. Additionally, MHG will acquire the production rights for NeoGraft as well as Venus VERO’s manufacturing and R&D facilities in San Jose, California.

    The third quarter of 2025 is when the deal is expected to conclude. Venus Concept (VERO) affirmed that it will keep looking for strategic options to increase the company’s long-term worth in spite of the transaction.

  • Venus Concept (VERO) Shares Rally Ahead of Earnings Release

    Venus Concept (VERO) Shares Rally Ahead of Earnings Release

    After the firm announced its forthcoming financial results for the first quarter of fiscal year 2025, shares of Venus Concept Inc. (NASDAQ: VERO) are seeing a big rise today, rising 22.36% to $3.041.

    Date of Financial Results Release

    Venus Concept said that on Thursday, May 15, 2025, before the market opens, its financial results for the first quarter of fiscal year 2025 will be released. At 8:00 a.m. Eastern Time on the same day as this release, the management team of the firm will have a conference call to go over the findings and conduct a Q&A session with analysts and stakeholders.

    Using Strategic Equity to Improve Financial Position

    This month, Venus Concept made a significant move to strengthen its financial stability by exchanging $11.0 million in subordinated convertible notes owned by Madryn Asset Management, LP affiliates. 379,311 shares of the company’s Series Y preferred stock were issued in exchange. This move is part of VERO’s broader capital structure optimization strategy, which shows the company’s commitment to debt reduction and posture for long-term, sustainable growth.

    Reduction in Debt Obligations

    Venus Concept’s total debt after the transaction was around $35.5 million, 54% less than the $76.7 million it owed on March 31, 2024. This is a notable 11% drop from the $39.7 million reported at the end of December 2024. The debt reduction provides VERO with greater financial freedom as it continues its operational transformation and works toward its long-term objectives.

    Collaboration with Madryn Asset Management

    Venus Concept stressed that Madryn Asset Management’s ongoing assistance and collaboration were essential to the transaction’s success. As VERO embarked on its next stage of innovation and growth with a new product roadmap, Madryn’s assistance not only made the debt conversion easier but also enhanced the company’s balance sheet.

  • Venus Concept Inc. (VERO) stock declined in the Current market; here is why?

    Venus Concept Inc. (VERO) stock declined in the Current market; here is why?

    Venus Concept Inc. (VERO) stock declined in the current market after the company announced that the FDA had granted clearance to market the Venus BlissMAX. VERO values at around $1.66, losing more than 7% from the previously closed value. At the end of the last trading session, the stock closed at $1.73. The stock traded volume in the previous trading session was around 173K shares.

    Reason for the VERO stock decline

    Venus Concept Inc. (VERO) announced that the FDA had granted clearance to market the Venus BlissMAX device in the United States. BlissMAX is a medical aesthetic platform that combines three technologies to reduce fat cellulite and strengthen muscles. For non-invasive abdominal and flank lipolysis in people with a BMI of 30 or less, BlissMAX utilizes innovative diode laser applicators. It also uses the (MP) 2 applicator for Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulseTM technology to reduce the appearance of cellulite. BlissMAX also includes the company’s FlexMAX EMS applicators, designed to condition and stimulate healthy muscles.

    BlissMAX is significant to our body treatments because it combines three body treatment technologies in a single, cost-effective platform. The BlissMAX delivers exceptional results with minimal downtime and high profitability per procedure. Furthermore, the company anticipates a local commercial launch in the United States by the end of the first quarter of fiscal 2022. The company expects that the BlissMAX is the only device on the market that combines fat laser reduction, cellulite reduction, and muscle conditioning.

    Effect on the stock

    The stock of Venus Concept Inc. (VERO) is declining due to its BlissMax approved by the FDA. But is expected that it will increase the company’s revenue, ultimately increase its valuation. As a result, its company’s stock is expected to increase in the future. Investors are investing in its stock for higher capital gain in the future.

    Conclusion

    BlissMax is a new addition to its arsenal, and it will increase the company’s revenue. Venus Concept Inc. (VERO) is looking forward to spreading the product in the United States by the end of the first quarter of 2022.